AIMS: Identification of biomarkers for stroke will aid our understanding of its aetiology, provide diagnostic and prognostic indicators for patient selection and stratification, and play a significant role in developing personalized medicine. We undertook the largest systematic review conducted to date in an attempt to characterize diagnostic and prognostic biomarkers in acute ischaemic and haemorrhagic stroke and those likely to predict complications following thrombolysis. METHODS: A comprehensive literature search was carried out to identify diagnostic and prognostic stroke blood biomarkers. Mean differences (MDs) and 95% confidence intervals (CIs) were calculated for each biomarker. RESULTS: We identified a total of 141 relevant studies, interrogating 136 different biomarkers. Three biomarkers (C-reactive protein, P-selectin and homocysteine) significantly differentiated between ischaemic stroke and healthy control subjects. Furthermore, glial fibrillary acidic protein levels were significantly different between haemorrhagic stroke and ischaemic stroke patients (MD 224.58 ng l⁻¹; 95% CI 25.84, 423.32; P= 0.03), high levels of admission glucose were a strong predictor of poor prognosis after ischaemic stroke and symptomatic intracerebral haemorrhage post-thrombolysis, glutamate was found to be an indicator of progressive (unstable) stroke (MD 172.65 µmol l⁻¹, 95% CI 130.54, 214.75; P= 0.00001), D-dimer predicted in-hospital death (MD 0.67 µg ml⁻¹, 95% CI 0.35, 1.00; P= 0.0001), and high fibrinogen levels were associated with poor outcome at 3 months (MD 47.90 mg l⁻¹, 95% CI 14.88, 80.93; P= 0.004) following ischaemic stroke. CONCLUSIONS: Few biomarkers currently investigated have meaningful clinical value. Admission glucose may be a strong marker of poor prognosis following acute thrombolytic treatment. However, molecules released in the bloodstream before, during or after stroke may have potential to be translated into sensitive blood-based tests.
AIMS: Identification of biomarkers for stroke will aid our understanding of its aetiology, provide diagnostic and prognostic indicators for patient selection and stratification, and play a significant role in developing personalized medicine. We undertook the largest systematic review conducted to date in an attempt to characterize diagnostic and prognostic biomarkers in acute ischaemic and haemorrhagic stroke and those likely to predict complications following thrombolysis. METHODS: A comprehensive literature search was carried out to identify diagnostic and prognostic stroke blood biomarkers. Mean differences (MDs) and 95% confidence intervals (CIs) were calculated for each biomarker. RESULTS: We identified a total of 141 relevant studies, interrogating 136 different biomarkers. Three biomarkers (C-reactive protein, P-selectin and homocysteine) significantly differentiated between ischaemic stroke and healthy control subjects. Furthermore, glial fibrillary acidic protein levels were significantly different between haemorrhagic stroke and ischaemic strokepatients (MD 224.58 ng l⁻¹; 95% CI 25.84, 423.32; P= 0.03), high levels of admission glucose were a strong predictor of poor prognosis after ischaemic stroke and symptomatic intracerebral haemorrhage post-thrombolysis, glutamate was found to be an indicator of progressive (unstable) stroke (MD 172.65 µmol l⁻¹, 95% CI 130.54, 214.75; P= 0.00001), D-dimer predicted in-hospital death (MD 0.67 µg ml⁻¹, 95% CI 0.35, 1.00; P= 0.0001), and high fibrinogen levels were associated with poor outcome at 3 months (MD 47.90 mg l⁻¹, 95% CI 14.88, 80.93; P= 0.004) following ischaemic stroke. CONCLUSIONS: Few biomarkers currently investigated have meaningful clinical value. Admission glucose may be a strong marker of poor prognosis following acute thrombolytic treatment. However, molecules released in the bloodstream before, during or after stroke may have potential to be translated into sensitive blood-based tests.
Authors: T Brott; H P Adams; C P Olinger; J R Marler; W G Barsan; J Biller; J Spilker; R Holleran; R Eberle; V Hertzberg Journal: Stroke Date: 1989-07 Impact factor: 7.914
Authors: Svetlana A Dambinova; Guerman A Khounteev; Galina A Izykenova; Igor G Zavolokov; Anna Y Ilyukhina; Alexander A Skoromets Journal: Clin Chem Date: 2003-10 Impact factor: 8.327
Authors: José Alvarez-Sabín; Carlos A Molina; Marc Ribó; Juan F Arenillas; Joan Montaner; Rafael Huertas; Esteban Santamarina; Marta Rubiera Journal: Stroke Date: 2004-10-07 Impact factor: 7.914
Authors: Anna Maria Gori; Betti Giusti; Benedetta Piccardi; Patrizia Nencini; Vanessa Palumbo; Mascia Nesi; Antonia Nucera; Giovanni Pracucci; Paolina Tonelli; Eleonora Innocenti; Alice Sereni; Elena Sticchi; Danilo Toni; Paolo Bovi; Mario Guidotti; Maria Rosaria Tola; Domenico Consoli; Giuseppe Micieli; Rossana Tassi; Giovanni Orlandi; Maria Sessa; Francesco Perini; Maria Luisa Delodovici; Maria Luisa Zedde; Francesca Massaro; Rosanna Abbate; Domenico Inzitari Journal: J Cereb Blood Flow Metab Date: 2017-03-07 Impact factor: 6.200
Authors: Andrea Rocco; Peter A Ringleb; Ulrike Grittner; Christian H Nolte; Alice Schneider; Simon Nagel Journal: Neurol Sci Date: 2015-07-25 Impact factor: 3.307
Authors: Reyna L VanGilder; Danielle M Davidov; Kyle R Stinehart; Jason D Huber; Ryan C Turner; Karen S Wilson; Eric Haney; Stephen M Davis; Paul D Chantler; Laurie Theeke; Charles L Rosen; Todd J Crocco; Laurie Gutmann; Taura L Barr Journal: J Clin Neurosci Date: 2013-08-23 Impact factor: 1.961
Authors: Yun-Ju Lai; Sandra K Hanneman; Rebecca L Casarez; Jing Wang; Louise D McCullough Journal: Am J Transl Res Date: 2019-08-15 Impact factor: 4.060
Authors: Helen C Segal; Annette I Burgess; Debbie L Poole; Ziyah Mehta; Louise E Silver; Peter M Rothwell Journal: Stroke Date: 2014-08-26 Impact factor: 7.914
Authors: Ulrich Dirnagl; Antoine Hakim; Malcolm Macleod; Marc Fisher; David Howells; Stuart M Alan; Gary Steinberg; Anna Planas; Johannes Boltze; Sean Savitz; Costantino Iadecola; Stephen Meairs Journal: Stroke Date: 2013-04-18 Impact factor: 7.914
Authors: Svetlana A Dambinova; Kerstin Bettermann; Theodore Glynn; Matthew Tews; David Olson; Joseph D Weissman; Richard L Sowell Journal: PLoS One Date: 2012-07-27 Impact factor: 3.240